This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Transfusion trial to help COVID-19 patients


An NIHR-supported trial is investigating whether convalescent plasma transfusions improve the speed of recovery and chances of survival for COVID-19 patients.

Convalescent plasma is the antibody-rich plasma of someone who has recovered from a virus.

It is part of the blood and may contain antibodies their immune system has produced in fighting COVID-19 which can be transfused into patients whose immune systems are struggling to fight the infection.

The REMAP-CAP trial is already underway in more than 50 hospitals across the UK including in Berkshire, Milton Keynes and Oxfordshire.

It is part of a suite of nationally-prioritised studies funded by NIHR and UK Research and Innovation (UKRI).

Study Chief Investigator Professor Anthony Gordon said: “The REMAP-CAP trial has been specifically designed to provide answers about the best treatment options for the most seriously ill with COVID-19.

“It is fully adaptive, meaning that new treatments can be added as we learn more, the sample size isn’t fixed and it keeps recruiting until it finds that a treatment is better, worse, or the same as another. 

“It also ‘learns’ from that data so that patients are more likely to receive those interventions that are performing best.”

There is some limited evidence of patient benefit from the use of convalescent plasma, and these clinical trials are needed to confirm the safety and effectiveness of transfusion.

NHS Blood and Transplant has already started collecting and freezing donations from recovered COVID-19 patients for use in trials.

Dr Gail Miflin, Chief Medical Officer, NHS Blood and Transplant, said: “As well as continuing to collect enough blood throughout this outbreak, we are also heavily involved in the national research response including major trials of this potential treatment.

“We are rapidly building our capability to collect plasma so that we can quickly move into supplying hospitals at scale, should the proposed trial demonstrate patient benefit.”

View other NIHR-supported studies into COVID-19 on the NIHR website.